invoX Pharma: InvoX Pharma Limited: InvoX Pharma's F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody

Bispecific antibody directed towards an undisclosed Takeda immuno-oncology target uses F-star's proprietary Fcab and mAb2 platforms InvoX Pharma Limited ("invoX")a U.K.-based wholly-owned subsidia...